Molecuence Corporation (Molecuence) is engaged in research, development, production and commercialization of novel pharmaceutical products. It is a wholly owned subsidiary of Mitsubishi Chemical Corp. The company is principally involved in the development of disease related biomarkers enables diagnosis and predicts accurate disease status. Currently, the company is engaged in the development of novel diagnostic methods for pancreatic cancer. Further, it is also involved in research and development of advanced biomarkers for stroke and cancer conditions. The company was formerly known as Zoegene Corporation. Molecuence works in partnership with the National Cancer Center Research Institute and Kyushu Institute. The company is headquartered in Yokohama, Japan.